Phase I Trial: SABR and Ipilimumab-Letter

Clin Cancer Res. 2017 Jan 1;23(1):320. doi: 10.1158/1078-0432.CCR-16-2495.

Susan M Hiniker¹, Sunil A Reddy², Susan M Swetter^{3

4}, Susan J Knox⁵

¹ Department of Radiation Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California. [email protected].
² Department of Medicine, Division of Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California.
³ Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Stanford, California.
⁴ Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
⁵ Department of Radiation Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California.

No abstract available

Publication types